Related Experiment Video

Updated: Aug 7, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes

Rajesh S Savkur1, Anne R Miller

  • 1Eli Lilly and Company, Diabetes Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA.

Expert Opinion on Investigational Drugs
|June 22, 2006
PubMed

Insights

New therapies targeting peroxisome proliferator-activated receptors (PPARs) show promise for treating Type 2 diabetes (T2D) and metabolic syndrome. This review covers current and emerging PPAR ligands for T2D treatment.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Drug Discovery

Background:

  • Rising global prevalence of Type 2 diabetes (T2D) and associated metabolic disorders necessitates novel therapeutic strategies.
  • Peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors, are key drug targets for metabolic syndrome.
  • PPAR-activating compounds are recognized for their therapeutic potential in managing T2D and metabolic anomalies.

Purpose of the Study:

  • To review currently marketed compounds that activate PPARs.
  • To describe the discovery and development of next-generation PPAR ligands.
  • To highlight potential treatments for T2D and metabolic syndrome.

Main Methods:

  • Literature review of existing and investigational PPAR ligands.
  • Analysis of drug development pipelines for T2D and metabolic syndrome therapies.
  • Focus on compounds targeting PPARs for metabolic regulation.

Main Results:

  • Several PPAR-activating compounds are currently available for T2D treatment.
  • Next-generation PPAR ligands are under active investigation.
  • Emerging ligands demonstrate potential for improved efficacy and safety profiles.

Conclusions:

  • PPARs remain a critical target class for T2D and metabolic syndrome.
  • Continued research into PPAR ligands is vital for advancing metabolic disease therapies.
  • The development of novel PPAR modulators offers hope for improved patient outcomes.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...